Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel drug discovery leverages SIMDAT Grid technology

16.09.2008
Substantial progress in pharmaceutical analysis within the European SIMDAT project. Grid technologies developed by GlaxoSmithKline (GSK), NEC, Inpharmatica (Galapagos), InforSense and Fraunhofer Institute for Algorithms and Scientific Computing SCAI provide a new business model in the life science sector.

Step change in life sciences. Within the European SIMDAT project, at GlaxoSmithKline (GSK) a substantial progress in pharmaceutical analysis has been achieved. It enables pharmaceutical companies to Virtualise and Globalise their Research and Development (R&D) chain, lowering costs as well as considerably improving knowledge exchange between industrial and academic partners.

"One of the most important R&D strategies to achieve a significant gain of efficiency is to tap into external knowledge and expertise through a network of external alliances, sharing the risk, reward and control. Given the large investments in drug research, Virtualisation provides a great savings potential," summarizes Professor Ulrich Trottenberg, director of Fraunhofer Institute for Algorithms and Scientific Computing SCAI, the SIMDAT project co-ordinator, the current challenges in pharmaceutical drug discovery.

GSK, with its firm foundation in science and a track record of turning its research into powerful, marketable drugs, spends more than £300,000 (US$562,000) every hour to find new medicines to treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. GSK is also a leader in the important area of vaccines and develops new treatments for cancer.

"With the distributed nature and diverse location of biological data for disease and medical treatment, it is becoming vital to be able to fast and flexible connect to these resources. Grid as a key part of Information Technology supports the organisations' rapid movement into the virtualised and now more globalised information market," says Rob Gill, Head of Biology Domain Architecture at GSK. "The SIMDAT Grid technologies developed by GlaxoSmithKline (GSK), NEC, Inpharmatica (Galapagos), InforSense and Fraunhofer Institute for Algorithms and Scientific Computing SCAI provide a new business model in the life science sector, which can be considered as a success of the project as a whole."

Usually, establishing new relationships by creating a new virtual organisation (VO) may take up to several months. But the "Data Grid" paradigm can reduce this to weeks or even days. The VO in this case demonstrates how a pharmaceutical company could partner with an academic group and a vendor company to look at a specific disease and drug target. The duration of this relationship depends on the questions asked and the costs incurred by the interaction. Biotech, on the other hand, has the opportunity to get access to new markets and, hence, is in the position to increase its commercial offer by implementing a finer grained product portfolio.

Knowledge exchange within SIMDAT is not bound to local infrastructure but is tending away from organisational, process and technology limitations. Thus, pharmaceutical companies like GSK have now the possibility to scale their business relationship with both biotech companies like Inpharmatica (Galapagos) and academic partners. That is, they can restrict themselves to exactly those resources they are interested in and are not forced to subscribe to a complete and costly product. This can be realised by new, grid-based middleware components, used to securely and transparently integrate distributed data repositories, in combination with distributed execution of process chains.

Through Virtualisation pharmaceutical companies like GSK are now capable of scaling their business relationship with both industrial and academic partners and take advantage of its great savings potential. In addition Globalisation is getting more and more crucial to keep up in an international context, especially considering the rate of growth of scientific and technical graduates in Asia is already outpacing the United States and Europe. Virtualisation has also the means to benefit from this wealth of knowledge along with developments in the global market.

Current industry applications can already take advantage of SIMDAT technologies. This was successfully demonstrated by a workflow-based test system implemented at GSK by InforSense, consisting of five different remote sites and including data services of two external companies. The development of this workflow is driven by the need to get high quality, state of the art analysis for pharmaceutical companies from wherever it is best sourced. Thus was shown that pharmaceutical R&D processes can be outsourced across multiple organizations, even if they are using different specifications. Thereby the central industrial requirement for a controlled and secure interaction has been fully addressed through internet security models provided by NEC.

As a powerful tool for knowledge exchange, SIMDAT technology broadens the scope of the drug discovery chain and is able to import the best of bread analysis from both academia and vendors at appropriate costs. It is an ideal showcase for potential providers who are interested in working with pharmaceutical partners in a more collaborative and beneficial manner rather than purely in a simple vendor consumer relationship.

SIMDAT has received research funding by the European Commission under the Information Society Technologies Programme (IST), contract number IST-2004-511438. Maximum Community contribution to project: 11 Mio Euro, Project start: 1 September 2004, Duration: 48 months, Partners involved: 27. The project is coordinated by the Fraunhofer Institute SCAI in Sankt Augustin, Germany.

GSK is one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases - HIV/AIDS, tuberculosis and malaria, and has developed some of the leading global medicines in these fields. Headquartered in the UK and with operations based in the US, it is one of the industry leaders, with an estimated seven percent of the world's pharmaceutical market.

Fraunhofer Institute for Algorithms and Scientific Computing SCAI conducts research in the field of computer simulations for product and process development, designs and optimizes industrial applications, and offers calculations on high-performance computers. The Fraunhofer Gesellschaft, umbrella organisation of SCAI, undertakes applied research of direct use to private and public enterprise.

InforSense goes beyond traditional business intelligence to provide a completely integrated suite of agile, visual and predictive intelligence solutions, enabling organizations to gain business and scientific insights and optimize their business-critical decision-making processes. Leading pharmaceutical, biotechnology, consumer goods, healthcare, financial services, manufacturing and communications companies around the world rely on InforSense to quickly, easily deliver intelligence and identify trends in data. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.

NEC Laboratories Europe's IT Research Division (NLE-IT) in St. Augustin, Germany, focuses on the area of Parallel and Distributed Computing, including Grid Technologies and High Performance Computing (HPC) software technologies and applications. Current Grid activities address future enterprise service infrastructures and integrated security solutions. NLE-IT develops technology to enable Service-Oriented Architecture (SOA)-based business processes, such as enterprise applications, to be created, managed and deployed on demand. Strategic research areas for realizing the vision of a global service economy include: next-generation SOA for cross-enterprise collaboration and eCommerce, future SOA runtime systems, Service Level Agreement (SLA) lifecycle management, service quality assurance, virtualization, and semantic technologies.

CONTACTS:

Fraunhofer Institute for Algorithms and Scientific Computing SCAI
Clemens-August Thole
Head of Department Numerical Software, SIMDAT coordinator
+49 (0) 2241 14 27 39
clemens-august.thole@scai.fraunhofer.de
GSK
Robert Gill & Li Du
MRD-IT Enterprise Architecture
+44 (0) 143 876 8121 & +44 (0) 143 876 3384
rob.w.gill@gsk.com & li.5.du@gsk.com
NEC
Falk Zimmermann
Chief Researcher
+49 (0) 2241 92 52 35
zimmermann@it.neclab.eu
InforSense
Moustafa Ghanem
Director of Research
+44 (0) 207 594 8357
mmg@inforsense.com
Weitere Informationen:
http://www.simdat.eu
http://www.gsk.com
http://www.scai.fraunhofer.de
http://www.inforsense.com
http://www.it.neclab.eu

Michael Krapp | Fraunhofer Gesellschaft
Further information:
http://www.scai.fraunhofer.de

More articles from Information Technology:

nachricht First machine learning method capable of accurate extrapolation
13.07.2018 | Institute of Science and Technology Austria

nachricht A step closer to single-atom data storage
13.07.2018 | Ecole Polytechnique Fédérale de Lausanne

All articles from Information Technology >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Research finds new molecular structures in boron-based nanoclusters

13.07.2018 | Materials Sciences

Algae Have Land Genes

13.07.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>